TY - JOUR
T1 - Average adherence to boosted protease inhibitor therapy, rather than the pattern of missed doses, as a predictor of HIV RNA replication
AU - Parienti, Jean Jacques
AU - Ragland, Kathleen
AU - Lucht, Frédéric
AU - De La Arnaud, Blanchardière
AU - Dargàre, Sylvie
AU - Yazdanpanah, Yazdan
AU - Dutheil, Jean Jacques
AU - Perré, Philippe
AU - Verdón, Renaud
AU - Bangsberg, David R.
N1 - Funding Information:
We thank Véronique Ronat, Isabelle Suaud, Anne-Catherine Cordier, and Pascale Goubin for their help in data collection and Fabien Chaillot for his expert administrative and regulatory support. We are grateful for the scientific collaboration of Isabelle Cohen-Codar and Richard A. Rhode. The ESPOIR cohort was supported by an Abbott Laboratories unrestricted grant (to Caen Côte de Nacre University hospital). The REACH cohort was supported by the National Institute of Mental Health (grant RO-54907) and the National Institute on Alcohol Abuse and Alcoholism (grant K-24 015287). We also acknowledge helpful suggestions regarding wording of the summary findings by 2 anonymous reviewers.
PY - 2010/4/15
Y1 - 2010/4/15
N2 - Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication
AB - Consecutive missed doses may differentially impact the efficacy of antiretroviral therapy associated with the use of a nonnucleoside reverse-transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI). In a cohort of 72 subjects receiving a boosted PI, average adherence to dosage was a better predictor of human immunodeficiency virus (HIV) replication than was the duration or frequency of treatment interruption. In contrast with an NNRTI, consecutive missed doses of a boosted PI did not emerge as a major risk factor for HIV replication
UR - http://www.scopus.com/inward/record.url?scp=77950266796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77950266796&partnerID=8YFLogxK
U2 - 10.1086/651419
DO - 10.1086/651419
M3 - Article
C2 - 20210643
AN - SCOPUS:77950266796
SN - 1058-4838
VL - 50
SP - 1192
EP - 1197
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 8
ER -